Tissue Doppler time intervals and derived indices in hypoplastic left heart syndrome.
Hannah R Bellsham-Revell, Shane M Tibby, Aaron J Bell...
https://pubmed.ncbi.nlm.nih.gov/22157969/Actively Recruiting
Led by The University of Hong Kong · Updated on 2026-07-28
30
Participants Needed
2
Research Sites
N/A
Total Duration
This research focuses on patients with a functional single ventricle who have undergone the Fontan procedure, a surgery that improves survival but still leaves patients at risk for complications like heart failure. The study evaluates the effects of the drug dapagliflozin, a sodium-glucose cotransporter 2 inhibitor SGLT2i, which is being studied for its potential to improve heart and exercise function in this group. Currently, there are no established heart failure treatments or guidelines for these patients, so this trial aims to explore a new therapeutic option. Participants will take oral dapagliflozin 10mg once daily for 12 weeks. This is an open-label, single-group trial conducted at two hospitals specializing in congenital heart disease. The treatment period includes baseline assessment and follow-up visits at 4 weeks and 12 weeks where exercise capacity and heart function will be evaluated. The study will assess changes in maximum oxygen consumption and other heart and exercise parameters. During the study, participants will undergo medical history reviews, physical exams, blood tests, electrocardiograms, echocardiography, urine pregnancy tests for women of childbearing potential, and quality-of-life questionnaires. Cardiopulmonary exercise testing will measure oxygen consumption and heart function at baseline and after treatment. Researchers will monitor safety and clinical events throughout the 3-month participation. The total trial duration is 2 years, with each participant involved for about 3 months.
CONDITIONS
The Effect of Dapagliflozin on Exercise and Cardiac Functional Status of Patients After Fontan Procedure
P
Prof Yiu Fai Cheung
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
The University of Hong Kong
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 12 weeks
Participants take dapagliflozin 10mg orally once daily for 12 weeks. They will have clinical assessments including exercise tests and heart imaging at the start, 4 weeks, and 12 weeks.
3 visits including baseline, 4-week, and 12-week visits
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Hannah R Bellsham-Revell, Shane M Tibby, Aaron J Bell...
https://pubmed.ncbi.nlm.nih.gov/22157969/Chin Poh, Tim Hornung, David S Celermajer...
https://pubmed.ncbi.nlm.nih.gov/32098807/John J V McMurray, David L DeMets, Silvio E Inzucchi...
https://pubmed.ncbi.nlm.nih.gov/30895697/Julio Núñez, Patricia Palau, Eloy Domínguez...
https://pubmed.ncbi.nlm.nih.gov/29663436/Gary D Lopaschuk, Subodh Verma
https://pubmed.ncbi.nlm.nih.gov/32613148/John J V McMurray, Scott D Solomon, Silvio E Inzucchi...
https://pubmed.ncbi.nlm.nih.gov/31535829/Susan M Fernandes, Doff B McElhinney, Paul Khairy...
https://pubmed.ncbi.nlm.nih.gov/19915891/Theresa A McDonagh, Marco Metra, Marianna Adamo...
https://pubmed.ncbi.nlm.nih.gov/34447992/Elena Sanz Pascual, Montserrat Bret Zurita, Jesus Diez Sebastián...
https://pubmed.ncbi.nlm.nih.gov/34900549/Rachael Cordina, Margherita Ministeri, Sonya V Babu-Narayan...
https://pubmed.ncbi.nlm.nih.gov/29472024/The University of Hong Kong
Lead Sponsor